awmsg logo



enfuvirtide (Fuzeon®)


Reference No. 124

Publication date:
28/05/2004


Appraisal information

enfuvirtide (Fuzeon®) 90 mg/ml powder and solvent for solution for injection


Company: Roche Products Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: 02/12/2003
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: Not available
Ministerial ratification: 01/03/2004

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of enfuvirtide within NHS Wales for the treatment of patients with HIV-1. It has been agreed the following restrictions should apply to its use: 1. Enfuvirtide should only be available to physicians in secondary care specialising in the management of patients with HIV. 2. Enfuvirtide must be used in accordance with criteria defined in the product's SPC and the UK British HIV Association (BHIVA) guidelines. AWMSG would also like to draw the attention of prescribers to the following statement: "AWMSG has concerns that reference in the Patient Product Information Sheet for enfuvirtide of returning vials to the pharmacy may be misinterpreted by patients and could result in them attempting to return a wider range of clinical waste to the pharmacy. Pharmacists, doctors and nurses may find it necessary to draw the attention of patients to the correct way to dispose of their clinical waste."
Final Appraisal Recommendation (FAR)
Download